Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation

Nature Reviews Cardiology

Volumn 9, Issue 7, 2012, Pages 385-391

  Cabral, Katherine P ^a   Ansell, Jack ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; WARFARIN;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EMBOLISM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STROKE; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FACTOR XA; HEMORRHAGE; HUMANS; MEDICATION ADHERENCE; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84862870793     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.19     Document Type: Review

References (59)

1. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 114, 119-125 (2006).
2. Hylek, E. M. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349, 1019-1026 (2003).
3. Hart, R. G., Benavente, O., McBride, R. & Pearce, L. A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492-501 (1999).
4. Waldo, A. L., Becker, R. C., Tapson, V. F. & Colgan, K. J. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol. 46, 1729-1736 (2005).
5. Ansell, J. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (Suppl. 6), 160S-198S (2008).
6. Singer, D. E. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (Suppl. 6), 546S-592S (2008).
7. Ogilvie, I. M., Newton, N., Welner, S. A., Cowell, W. & Lip, G. Y. H. Under use of oral anticoagulants in atrial fibrillation; a systematic review. Am. J. Med. 123, 638-645 (2010).
8. Wisler, J. W. & Becker, R. C. Oral factor Xa inhibitors for the long-term management of ACS. Nat. Rev. Cardiol. http://dx.doi.org/10.1038/ nrcardio.2012.18.
9. Butenas, S. & Mann, K. G. Kinetics of human factor VII activation. Biochemistry 36, 1904-1910 (1996).
10. Alexander, J. H. & Singh, K. P. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am. J. Cardiovasc. Drugs 5, 279-290 (2005).
11. Eriksson, B. I., Quinlan, D. J. & Weitz, J. I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmacokinet. 48, 1-22 (2009).
12. Bauer, K. A. New anticoagulants: anti IIa vs. anti Xa-is one better? J. Thromb. Thrombolysis 21, 67-72 (2006).
13. Rai, R., Sprengeler, P. A., Elrod, K. C. & Young, W. B. Perspectives on factor Xa inhibition. Curr. Med. Chem. 8, 101-119 (2001).
14. Kubitza, D., Becka, M., Wensing, G., Voith, B. & Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880 (2005).
15. Turpie, A. G. G. New oral anticoagulants in atrial fibrillation. Eur. Heart J. 29, 155-165 (2007).
16. Eriksson, B. I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008).
17. Kakkar, A. K. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 372, 31-39 (2008).
18. Lassen, M. R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
19. Turpie, A. G. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 373, 1673-1680 (2009).
20. Turpie, A. G. G. et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding [abstract 36]. Blood 112, 18-19 (2008).
21. Cohen, A. T. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. American Heart Association [online], http://my.americanheart.org/idc/groups/ahamah-public/@wcm/ @sop/@scon/documents/downloadable/ucm-425442.pdf (2011).
22. ROCKET AF study investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159, 340-347 (2010).
23. Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
24. US Department of Health and Human Sciences. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm (2011).
25. Fleming, T. R. & Emerson, S. S. Evaluating rivaroxaban for nonvalvular atrial fibrillation-regulatory considerations. N. Engl. J. Med. 365, 1557-1559 (2011).
26. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
27. Lassen, M. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594-604 (2009).
28. Lassen, M. R., Gallus, A. S., Pineo, G. F. & Raskob, G. E. The ADVANCE 2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement [abstract]. J. Thromb. Haemost. 7 (Suppl. 2), LB-MO-005 (2009).
29. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00457002 (2011).
30. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00643201 (2012).
31. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00633893 (2012).
32. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00252005 (2010).
33. Ufer, M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost. 103, 572-585 (2010).
34. Connolly, S. J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
35. Lopes, R. D. et al. Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159, 131-139 (2010).
36. Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
37. Masumoto, H. et al. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban [online], http://www.aapsj.org/ abstracts/AM-2010/W4308.pdf (2012).
38. Eikelboom, J. W. & Weitz, J. I. New anticoagulants. Circulation 121, 1523-1532 (2010).
39. Fuji, T., Fujita, S., Tachibana, S. & Kawai, Y. Randomized, double blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty [abstract]. Blood 112, a34 (2008).
40. Raskob, G. et al. Randomized, double blind, multi-dose trial of the oral factor Xa inhibitor DU-176b versus LMW heparin (dalteparin) for the prevention of venous thromboembolism after total hip replacement [abstract]. Eur. Heart J. 29 (Abstract Suppl.) a609 (2008).
41. Weitz J. l. et al. Randomized, parallel group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb. Haemost. 104, 633-641 (2010).
42. Ruff, C. T. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160, 635-641 (2010).
43. Ezekowitz, M. D. et al. A phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa) [online], http://assets.cardiosource.com/ ezekowitz-explore1.ppt (2010).
44. Khoo, C. W., Tay, K. H., Shantsila, E. & Lip, G. Novel oral anticoagulants. Int. J. Clin. Pract. 63, 630-641 (2009).
45. Portola Pharmaceuticals. PRT064445: FXa Inhibitor Antidote [online], http://www.portola.com/PRT064445-Fxa-Inhibitor-Antidote (2011).
46. Janssen. Xarelto® (rivaroxaban) tablets, for oral use: prescribing information [online], http://www.xareltohcp.com/sites/default/files/pdf/xarelto- 0.pdf (2011).
47. Gruber, A., Marzec, U. M., Buetehorn, U., Hanson, S. & Perzborn, E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates [abstract 3825]. Blood 112, 1307 (2008).
48. Eerenberg, E. S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in health subjects. Circulation 124, 1573-1579 (2011).
49. Lu, G. et al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract 983]. Blood 112, 362 (2008).
50. Yasuda, K. et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharm. Exp. Ther. 303, 323-332 (2002).
51. Lin, J. H., Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98 (2003).
52. Walenga, J. M. & Adiguzel, C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int. J. Clin. Pract. 64, 956-967 (2010).
53. Weitz, J. I., Hirsch, J. & Samama, M. M. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (Suppl. 6), 234S-256S (2008).
54. DiMatteo, M. R. et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med. Care 40, 794-811 (2002).
55. Cramer, J. A. Partial medication compliance: the enigma in poor medical outcomes. Am. J. Manag. Care 1, 167-174 (1995).
56. Sullivan, S. D., Kreling, D. H., Hazlet, T. K. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J. Res. Pharm. Econ. 2, 19-33 (1990).
57. Dunbar-Jacob, J. et al. Adherence in chronic disease, in Annual Review of Nursing Research 18th edn (eds Fitzpatric, J. J. & Goeppinger, J.) 48-90 (Springer, New York, 2000).
58. Kimmel, S. E. et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch. Intern. Med. 167, 229-235 (2007).
59. Ansell, J. E. Optimizing the efficacy and safety of oral anticoagulant therapy: high quality dose management, anticoagulation clinics, and patient self-management. Semin. Vas. Med. 3, 261-269 (2003).